Background
Brian Rifkin
ICRAKI-ng the code on RRT

This week, we will discuss intermittent hemodialysis versus continuous hemodialysis for AKI in the ICU (ICRAKI study)

ICRAKI-ng the code on RRT
news
swapnil hiremath
Kidney Week in Denver: Day 3

Day 3 : yet another IgA trial, and we are back with some flozin news: in ADPKD, their effect on hemoglobin, and on BP (with finerenone)

Kidney Week in Denver: Day 3
news
swapnil hiremath
Kidney Week in Denver: Day 2

Day 2 was less exciting: we cover 1 IgA trial (Ravulizumab) along with another calcimimetic, and a pentoxifylline meta-analysis.

Kidney Week in Denver: Day 2
news, Background
Milagros Flores
Kidney Week in Denver: Day 1

Day of Kidney Week 2026. The NephJC crew discusses 6 studies, including some blockbustr IgA news.

Kidney Week in Denver: Day 1
Background
Brian Rifkin
Can Dialysis Outshine Transplant in the Elderly?

This week, we will discuss whether decreased donor transplantation improves mortality in all patients. In this target trial emulation standard donor, extended donor, donation after brain death and donation after cardiac death outcomes are compared across age groups with different co-morbid conditions.

Can Dialysis Outshine Transplant in the Elderly?

hemodiafiltration

TenXeetNephJC? TenPostNephJC? It's HDF and CONVINCE anyway.

Huge trial on our core work, catch-up here

HDF vs HD: Need for CONVINCE-ing Evidence

HDF vs HD: Need for CONVINCE-ing Evidence

This week, we will discuss CONVINCE, a randomized controlled trial, about the long-lasting battle between hemodialysis and hemodiafiltration. Will it convince the unconvinced, or will it diffuse even more uncertainty into community?